164 related articles for article (PubMed ID: 36063619)
1. Does neoadjuvant chemotherapy regimen affect sarcopenia status in patients with breast cancer?
Jang MK; Park S; Park C; Doorenbos AZ; Go J; Kim S
Breast; 2022 Dec; 66():1-7. PubMed ID: 36063619
[TBL] [Abstract][Full Text] [Related]
2. Hematologic toxicities, sarcopenia, and body composition change in breast cancer patients undergoing neoadjuvant chemotherapy.
Jang MK; Park S; Park C; Doorenbos A; Go J; Kim S
Support Care Cancer; 2023 Jun; 31(7):419. PubMed ID: 37354335
[TBL] [Abstract][Full Text] [Related]
3. Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP).
Le D; Vargo C; Collins S; Williams N; Palettas M; Berger M
Target Oncol; 2022 Mar; 17(2):167-175. PubMed ID: 35325355
[TBL] [Abstract][Full Text] [Related]
4. Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence.
de Pinho IS; Luz P; Alves L; Lopes-Brás R; Patel V; Esperança-Martins M; Gonçalves L; Freitas R; Simão D; Galnares MR; Fernandes I; Criado SA; Casado SG; Cañada JB; Vega IMS; Costa JG; Fernandes AS; de Sousa RT; Costa L
Clin Drug Investig; 2023 Sep; 43(9):691-698. PubMed ID: 37479867
[TBL] [Abstract][Full Text] [Related]
5. Body composition change during neoadjuvant chemotherapy for breast cancer.
Jang MK; Park S; Park C; Doorenbos AZ; Go J; Kim S
Front Oncol; 2022; 12():941496. PubMed ID: 36091109
[TBL] [Abstract][Full Text] [Related]
6. Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP.
Ji JH; Bae SJ; Kim SG; Kim MH; Kim GM; Sohn J; Jeong J; Kim JH; Ahn SG
Cancer Med; 2023 Jan; 12(2):1409-1417. PubMed ID: 35837812
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
Spring L; Niemierko A; Haddad S; Yuen M; Comander A; Reynolds K; Shin J; Bahn A; Brachtel E; Specht M; Smith BL; Taghian A; Jimenez R; Peppercorn J; Isakoff SJ; Moy B; Bardia A
Breast Cancer Res Treat; 2018 Dec; 172(3):733-740. PubMed ID: 30220055
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
9. Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience.
Kim JY; Nam SJ; Lee JE; Yu J; Chae BJ; Lee SK; Ryu JM; Ahn JS; Im YH; Kim SW; Park YH
Cancer Res Treat; 2022 Oct; 54(4):1091-1098. PubMed ID: 35008143
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
Lopresti ML; Bian JJ; Sakr BJ; Strenger RS; Legare RD; Fenton M; Witherby SM; Dizon DS; Pandya SV; Stuckey AR; Edmondson DA; Gass JS; Emmick CM; Graves TA; Cutitar M; Olszewski AJ; Sikov WM
Breast Cancer Res Treat; 2021 Aug; 189(1):93-101. PubMed ID: 34086171
[TBL] [Abstract][Full Text] [Related]
11. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
12. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Hassett MJ; Li H; Burstein HJ; Punglia RS
Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.
; Mari A; D'Andrea D; Kimura S; Resch I; Shariat SF; Klatte T
Urol Int; 2018; 101(2):197-200. PubMed ID: 30089304
[TBL] [Abstract][Full Text] [Related]
15. Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study.
Rinninella E; Strippoli A; Cintoni M; Raoul P; Vivolo R; Di Salvatore M; Genco E; Manfredi R; Bria E; Tortora G; Gasbarrini A; Pozzo C; Mele MC
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33809587
[TBL] [Abstract][Full Text] [Related]
16. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
Ubachs J; Koole SN; Lahaye M; Fabris C; Bruijs L; Schagen van Leeuwen J; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham M; van Dam P; Vuylsteke P; Bastings J; Kruitwagen RFPM; Lambrechts S; Olde Damink SWM; Rensen SS; Van Gorp T; Sonke GS; van Driel WJ
Gynecol Oncol; 2020 Dec; 159(3):706-711. PubMed ID: 33019981
[TBL] [Abstract][Full Text] [Related]
17. Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
Wood N; Morton M; Shah SN; Yao M; Barnard H; Tewari S; Suresh A; Kollikonda S; AlHilli MM
Gynecol Oncol; 2023 Feb; 169():55-63. PubMed ID: 36508759
[TBL] [Abstract][Full Text] [Related]
18. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
20. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
